A Phase 2 interventional study of GTx 024 and Placebo in Stress Urinary Incontinence, sponsored by GTx. Completed at 62 sites in United States. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-24.
Sponsored by GTx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Urinary Incontinence, Stress with a site in United States — 27 open to participants now, 40 under way, 3 of them phase 3. Urinary Incontinence, Stress · United States.
Among the 189 studies in Urinary Incontinence, Stress with a site in United States, this one is the 11th largest by enrollment of the 163 interventional ones that give a count, is one of 15 that started in 2017, is one of 12 in phase 2, and was the 95th registered.
653 studies on the registry are indexed under Urinary Incontinence, Stress; 121 are open to participants now.
Browse Urinary Incontinence, Stress studies →27 of the 189 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Canada, China and 6 more countries
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 18–50 · Women only
University of Rochester · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 74 Urinary Incontinence, Stress studies recruiting now, 42 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 23 · Phase 4 15
First in 2001; this study’s year is marked. 15 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 491 is above the median of 68 across 508 interventional studies indexed under Urinary Incontinence, Stress.
Median enrollment 98 across the 163 interventional studies, 98 across the 26 observational. Of the 129 that completed or were terminated, 56 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 189 have an industry lead sponsor. The 10 most frequent:
GTx is the lead sponsor of 19 studies on the registry; none are open to participants now.
GTx has 4 studies filed under Urinary Incontinence, Stress — fewer than ten, so there is no comparison to draw.
9 of the studies in Urinary Incontinence, Stress with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06968741UroMems SASA Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS) | 2026-12 |
| NCT06111209Brigham and Women's HospitalThe Anabolic Effect of Testosterone on Pelvic Floor Muscles | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
| NCT06706362Ohio State UniversityAssessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study) | 2027-04-15 |
| NCT07008898University of Alabama at BirminghamSequence of Midurethral Sling Placement During Robotic Sacrocolpopexy | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 189 studies in Urinary Incontinence, Stress with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GTx-024 is an orally bioavailable and tissue-selective nonsteroidal selective androgen receptor modulator (SARM) that has demonstrated androgenic and anabolic activity and is currently being evaluated as a potential treatment for stress urinary incontinence (SUI) in postmenopausal women. Urinary incontinence and pelvic floor disorders are major health problems for women, especially as they age. Pelvic floor muscle relaxation has been found to correlate with lower urinary tract symptoms including SUI. Muscles of the pelvic floor and lower urinary tract are crucial for supporting the pelvic organs and micturition; however, damage to the muscles or lack of hormonal stimulation are thought to contribute to pelvic organ prolapse and urinary incontinence. Although anabolic steroids may increase muscle mass and strength, lack of oral bioavailability and known potential risks have limited their use. Nonsteroidal SARMs have potential to achieve benefits of anabolic steroid therapy (improved muscle mass, cholesterol/triglyceride levels, glucose metabolism, and bone density) with fewer adverse effects, such as hirsutism and acne, in women. Both nonclinical and clinical data suggest that SARMs may provide a new therapeutic option for pelvic floor and lower urinary tract disorders, as both testosterone and its more potent metabolite, dihydrotestosterone, have anabolic effects on muscle.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
Drug: GTx 024
Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
Drug: GTx 024
Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
Drug: Placebo
Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
Also known as: Enobosarm
Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12
Mean number of subject-reported stress incontinence episodes per day through a responder analysis, where a responder is defined as having a ≥ 50% reduction at the end of treatment (Week 12) compared to baseline in the number of stress incontinence episodes
Time frame: 12 Weeks
| Milestone | 1 mg GTx-024 | 3 mg GTx-024 | Matching Placebo |
|---|---|---|---|
| Started | 163 | 163 | 165 |
| Completed | 141 | 132 | 138 |
| Not completed | 22 | 31 | 27 |
| Withdrew: Adverse event | 5 | 8 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Noncompliance with study drug | 2 | 1 | 1 |
| Withdrew: Sponsor decision | 0 | 1 | 2 |
| Withdrew: Not reported | 15 | 21 | 19 |
Mean number of subject-reported stress incontinence episodes per day through a responder analysis, where a responder is defined as having a ≥ 50% reduction at the end of treatment (Week 12) compared to baseline in the number of stress incontinence episodes
| Participants | 1 mg GTx-024 | 3 mg GTx-024 | Matching Placebo |
|---|---|---|---|
| Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12 | 94 | 96 | 87 |
Collected over 7 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 mg GTx-024 | 0/163 (0%) | 3/163 (1.8%) | 105/163 (64.4%) |
| 3 mg GTx-024 | 0/163 (0%) | 2/163 (1.2%) | 104/163 (63.8%) |
| Matching Placebo | 0/165 (0%) | 4/165 (2.4%) | 96/165 (58.2%) |
| Event | 1 mg GTx-024 | 3 mg GTx-024 | Matching Placebo |
|---|---|---|---|
| acute myocardial infarctionCardiac disorders | 1/163 | 0/163 | 0/165 |
| goiterEndocrine disorders | 0/163 | 1/163 | 0/165 |
| hip fractureInjury, poisoning and procedural complications | 1/163 | 0/163 | 0/165 |
| cerebral vascular accidentNervous system disorders | 0/163 | 1/163 | 0/165 |
| dysaesthesiaNervous system disorders | 1/163 | 0/163 | 0/165 |
| abscessed limbInfections and infestations | 0/163 | 0/163 | 1/165 |
| osteomyelitisInfections and infestations | 0/163 | 0/163 | 1/165 |
| spinal disorderMusculoskeletal and connective tissue disorders | 0/163 | 0/163 | 1/165 |
| pulmonary congestionRespiratory, thoracic and mediastinal disorders | 0/163 | 0/163 | 1/165 |
| respiratory failureRespiratory, thoracic and mediastinal disorders | 0/163 | 0/163 | 1/165 |
| Event | 1 mg GTx-024 | 3 mg GTx-024 | Matching Placebo |
|---|---|---|---|
| urinary tract infectionInfections and infestations | 17/163 | 29/163 | 18/165 |
| headacheNervous system disorders | 3/163 | 12/163 | 7/165 |
| upper respiratory tract infectionInfections and infestations | 7/163 | 7/163 | 10/165 |
| oedema peripheralGeneral disorders | 7/163 | 3/163 | 1/165 |
| nasopharyngitisInfections and infestations | 4/163 | 7/163 | 6/165 |
| blood creatinine increaseInvestigations | 7/163 | 0/163 | 1/165 |
| nauseaGastrointestinal disorders | 4/163 | 4/163 | 7/165 |
| hypertensionVascular disorders | 3/163 | 6/163 | 2/165 |
| dry mouthGastrointestinal disorders | 1/163 | 5/163 | 4/165 |
| insomniaPsychiatric disorders | 0/163 | 5/163 | 1/165 |
| Age, Continuous(years) | 1 mg GTx-024 | 3 mg GTx-024 | Matching Placebo | Total |
|---|---|---|---|---|
| Median | 60 (42 to 80) | 59 (40 to 79) | 58 (44 to 80) | 59 (40 to 80) |
| Sex: Female, Male(Participants) | 1 mg GTx-024 | 3 mg GTx-024 | Matching Placebo | Total |
|---|---|---|---|---|
| Female | 163 | 163 | 165 | 491 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | 1 mg GTx-024 | 3 mg GTx-024 | Matching Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 13 | 10 | 15 | 38 |
| Not Hispanic or Latino | 149 | 152 | 150 | 451 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | 1 mg GTx-024 | 3 mg GTx-024 | Matching Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 2 | 1 | 6 |
| Asian | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 25 | 20 | 12 | 57 |
| White | 131 | 139 | 150 | 420 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 0 | 4 |
| Baseline number of stress incontinence episodes per day(episodes per day) | 1 mg GTx-024 | 3 mg GTx-024 | Matching Placebo | Total |
|---|---|---|---|---|
| Mean | 4.588 (3 to 11.67) | 4.329 (3 to 12.67) | 4.459 (3 to 12) | 4.4 (3 to 12.67) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Sep 2018, 13 months.
Results were first posted in Nov 2020, 2 years 1 month after primary completion.
Of 15 phase 2 interventional studies under Urinary Incontinence, Stress, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ostarine
Urinary Incontinence, Stress →
GTx